ONO-4538 Multicenter, Open-label, Uncontrolled, Phase I Multiple Dose Study in Solid Tumor
Status: Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 09 Oct 2018
Price : $35 *
At a glance
- Drugs Nivolumab (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- Sponsors Ono Pharmaceutical
- 30 Sep 2018 Planned primary completion date changed from 1 Dec 2015 to 1 Dec 2019.
- 18 Jan 2015 Status changed from not yet recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 14 Oct 2014 New trial record